Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 4/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260511 | 0.93 | RXFP1 (0.75) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL12310429 | 0.91 | RXFP1 (0.72) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL17997357 | 0.88 | RXFP1 (0.68) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL10113827 | 0.88 | TRPA1 (0.74) | RXFP1MAPTHTTTHRBTRPA1 | |
| SCHEMBL10114655 | 0.87 | RXFP1 (0.81) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL14754391 | 0.86 | THRB (0.80) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL10114196 | 0.86 | RXFP1 (0.79) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL10114557 | 0.86 | RXFP1 (1.00) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL4533692 | 0.85 | RXFP1 (0.78) | RXFP1MAPTHTTGAATHRB | |
| SCHEMBL10114140 | 0.84 | RXFP1 (0.76) | RXFP1MAPTHTTGAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | RXFP1 941/4885MAPT 278/4885HTT 29/4885 |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | RXFP1 941/4885MAPT 278/4885HTT 29/4885 |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | RXFP1 1348/4885MAPT 540/4885HTT 1494/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | RXFP1 423/4885MAPT 846/4885HTT 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.